ArticleDiscover oncology2026
Opioid signaling-related genes and their prognostic role in hepatocellular carcinoma: insights from bioinformatics and functional studies.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a highly lethal malignancy with limited effective treatment options. Opioid signaling related genes (including lncRNAs) (OSRGs) have been implicated in HCC progression, yet their prognostic significance and roles in tumor biology remain poorly understood. This study aimed to investigate the relationship between OSRGs and biological characteristics of HCC, providing insights for targeted therapies. Gene expression data from TCGA-LIHC were analyzed using DESeq2. Gene Set Enrichment Analysis (GSEA) of OSRGs was performed with cluster Profiler. Kaplan-Meier (KM) analysis assessed survival differences between high- and low-expression groups. Unsupervised clustering using Consensus ClusterPlus identified two clusters based on 18 OSRGs. A risk model was constructed using 5 OSRGs (G6PD, KIF20A, MSC-AS1, TFF3, ZFPM2-AS1) through LASSO and Cox regression and validated in training and test datasets. Immune cell infiltration and drug sensitivity were analyzed using CIBERSORT and oncoPredict, respectively. qRT-PCR was used to assess gene expression levels, while Transwell assays evaluated the functions of the 5 OSRGs in HCC cells. Additionally, an orthotopic model was employed to investigate the role of KIF20A. We observed that cluster 1 had an unfavorable prognosis. The risk model revealed significant tumor microenvironment and drug sensitivity differences between high- and low-risk groups. Silencing the 5 OSRGs inhibited HCC cell migration and invasion, with KIF20A suppression significantly reducing tumor growth in vivo. This study highlights the strong predictive ability of the risk model based on 5 OSRGs and the oncogenic role of these genes in HCC, potentially providing a foundation for prognosis and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.